Is Shionogi going global as a pharmaceutical company from Japan, or simply buying growth while its […]
Daiichi Sankyo is no longer best understood as a successful Japanese pharma company with a strong […]
Japan wants biotechnology to become a larger part of its economy by 2030. That is the […]
Japan is one of the world’s most demanding healthcare markets. It is also one of the […]
Takeda’s savings programme is no longer an abstract investor slide. It has moved from corporate language […]
The JPY 200 billion savings target currently dominating Takeda’s internal dialogue isn’t just a number on […]
For too long, if you ask me, the Japan pharmaceutical market opportunity has been treated as […]